Skip To Main Content
Barbara Pistilli on Muck Rack

Barbara Pistilli

As seen in: Color Research & Application, Nature, MDPI, JAMA Network, JAMA Oncology, Cell Press, Cancer Epidemiology, Biomarkers & Prevention, The Bakersfield Californian, ONCOLOGY journal, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A modular framework for antibody–drug conjugate biomarkers

|
By Jia Liu, Dan-Yun Ruan, Nicholas McNamee, Roger R. Reddel, Hao-Xiang Wu, Qi Meng, Rui-hua Xu, Vivek Subbiah, David Rimm, Barbara Pistilli
| Nature Verified
Abstract The availability of approved antibody–drug conjugates (ADCs) has rapidly expanded across oncology indications, yet biomarker development remains dominated by semi-quantitative immunohistochemistry. Robust biomarkers are needed to improve patient selection, guide therapeutic sequencing and identify resistance mechanisms that inform rational combinations.
Open in Who Shared Issue with article?

Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors

|
By Antonio Di Meglio, Camila Chiodi, Julie Havas, Elise M. Martin, Élise Martin, Martina Pagliuca, Mariam Chichua, Emma Gillanders, Guillemette Jacob, Aurélie Bertaut, Diane Boinon, Barbara Pistilli, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Courèche Guillaume Kaderbhai, Anne Kieffer, Olivier Tredan, Christelle Levy, Olivier Rigal, Matteo Lambertini, Stefan Michiels, Fabrice André, Gwenn Menvielle, Maria Alice Franzoi, Ines Vaz-Luis, Petya Zyumbileva, Pietro Lapidari, Romaine Desjardin, Aude Barbier
| JAMA Network Verified
Research Study Attrition and Participant-Informed Retention Strategies Among Cancer Survivors Supplement 1. eTable 1. Overall characteristics of the CANTO cohort eTable 2. Multivariable logistic regression models of factors associated with non-responsiveness at Y-4 and Y-6 eTable 3. Characteristics of participants that were excluded vs. included in the complete-case analyses at Y-4 and Y-6 because of missing baseline data eTable 4.
Open in Who Shared Issue with article?

Antibody-drug conjugates in precision oncology

|
By Barbara Pistilli, Raffaele Colombo, Maria Fernanda Mosele, Sarat Chandarlapaty
| Cell Press Verified
Keywords antibody-drug conjugates ADCs precision medicine ADC toxicity mechanisms of action mechanisms of resistance ADC combinations Introduction Antibody-drug conjugates (ADCs) are innovative and complex therapeutic entities that have transformed cancer treatment.1,2 Initial clinical benefit was achieved in hematological malignancies, with gemtuzumab ozogamicin being the first ADC to receive Food and Drug Administration (FDA) accelerated approval in 2000 for adults with CD33-positive acute...
Open in Who Shared Issue with article?
See all 19 licensed articles (21 Total)